Taysha Gene Therapies (TSHA) Non-Current Assets (2020 - 2026)
Taysha Gene Therapies' (TSHA) quarterly Non-Current Assets came in at $18.1 million in Q1 2026, up 2.53% year-on-year from $17.7 million in Q1 2025, and up 9.02% quarter-over-quarter from $16.6 million in Q3 2025.
Taysha Gene Therapies (TSHA) Non-Current Assets (2020 - 2026) Analysis & Trends
Taysha Gene Therapies has disclosed Non-Current Assets across 7 years of filings, most recently posting $18.1 million for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | Taysha Gene Therapies | 2.36 Bn | 2.36 Bn | - | 18.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.10 Mn |
| Sep 30, 2025 | 16.60 Mn |
| Jun 30, 2025 | 17.07 Mn |
| Mar 31, 2025 | 17.65 Mn |
| Sep 30, 2024 | 18.66 Mn |
| Jun 30, 2024 | 21.92 Mn |
| Mar 31, 2024 | 22.40 Mn |
| Sep 30, 2023 | 23.96 Mn |
| Jun 30, 2023 | 27.43 Mn |
| Mar 31, 2023 | 29.24 Mn |
| Sep 30, 2022 | 68.47 Mn |
| Jun 30, 2022 | 65.50 Mn |
| Mar 31, 2022 | 59.09 Mn |
| Sep 30, 2021 | 43.87 Mn |
| Jun 30, 2021 | 34.56 Mn |
| Mar 31, 2021 | 3.20 Mn |
| Sep 30, 2020 | 28,000.00 |